MENTRIK Biotech LLC
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2010-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.mentrik.com
Phase I Study of Subcutaneous Ocaratuzumab in Patients With Previously Treated CD20+ B-Cell Malignancies
Phase 1
- Conditions
- Previously Treated CD20+ B-cell Malignancies
- Interventions
- Biological: ocaratuzumab
- First Posted Date
- 2013-05-21
- Last Posted Date
- 2014-03-03
- Lead Sponsor
- Mentrik Biotech, LLC
- Target Recruit Count
- 9
- Registration Number
- NCT01858181
- Locations
- 🇺🇸
Universtity of Texas Southwestern Medical Center, Dallas, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath